An 82-year-old man with a low-grade malignant non-Hodgkin lymphoma and an IgG, X monoclonal gammopathy presented a recently acquired bleeding tendency, characterized by recurrent epistaxis, easy bruising, and episodes of melena, requiring packed red blood cell transfusions. Coagulation studies showed a von Willebrand factor ( In the present study, a patient with a low-grade malignant B-cell non-Hodgkin lymphoma and a monoclonal IgG3 X gammopathy is described in whom an IgM autoantibody directed against the collagen binding domains of vWF is implicated in the pathogenesis of the acquired deficiency of vWF. We conclude that the IgM autoantibody inhibits the vWF:CBA activity by reacting with an epitope present on both the glycoprotein Ib and A3 domains of vWF.
CASE REPORT
A 82-year-old man with an IgG, A paraprotein (5 g/L) was referred to our department in 1989 for further analysis of a prolonged partial thromboplastin time discovered before a liver biopsy in the staging procedure of a non-Hodgkin lymphoma. Physical examination showed a slight hepatosplenomegaly, without enlarged lymph nodes. Hemoglobin levels and leukocyte, lymphocyte, and platelet counts were normal, as were the serum values for total lgG, IgA, and IgM. The bone marrow aspirate showed a nonnocellular hematopoiesis with 8% monoclonal plasma cells (cIgM+G A). Additionally, a monoclonal B-cell population (slgM A) represented 5% and 2 1 % of the total B-cell population in blood and bone marrow, respectively. Skeletal x-rays showed no osteolytic lesions. The diagnosis was made as low-grade malignant non-Hodgkin lymphoma stage IV with paraproteinemia IgG3 A.
Before 1989, the patient had no personal or family history of a bleeding tendency. Previous hemostatic challenges (appendectomy, dental extractions, and cholecystectomy) were uneventful. From 1989 on, the patient developed several episodes of easy bruising, recurrent epistaxis, and severe gastrointestinal blood loss, necessitating extensive replacement therapy with packed red blood cells and factor VI11 (FVIII)/vWF concentrates. Gaatrointestinal radiographic and endoscopic studies did not show a source of blood loss, except for a mild gastritis at one occasion. A transurethral prostatectomy was successfully performed with the administration of DDAVP and frequent cryoprecipitate infusions. However, a trial of cyclophosphamide (2 mgikg body weight) for 6 weeks did not improve the coagulation defect.
MATERIALS AND METHODS
Coagulation assays. Bleeding times were measured according to Ivy et al." Platelets were counted in EDTA blood samples using the Platelet Analyzer 810 (Baker Instruments, Allentown, PA). Platelet aggregation induced by 0.63 and 1.75 mg/mL ristocetin (H. Lundbeck CO, Copenhagen, Denmark) was recorded with the use of a serial aggregometer (Payton model 300B; Scarborough, Canada) in platelet-rich plasma at a standard count of 200 X 1 0 9 L FVIII coagulant activity (FVI1I:C) was assayed by means of the Automatic Coagulation Laboratory (ACL; Instrumental Laboratory, Ijsselstein, The Netherlands) using FVIII-deficient plasma (Ortho Diagnostic Systems, Beerse, Belgium).
vWF assays. vWF antigen (vWF:Ag) was assayed by an enzyme-linked immunosorbent assay (ELISA), as described by Cejka." Ristocetin cofactor activity (vWF:RCoF) was assayed with formalin-fixed platelets" using a PAP4 Model Aggregometer @io-Data Corp. Hatboro, PA). was diluted in 1,000 pL PBS-Tween-Albumin. After incubation overnight at 4"C, 40 pL of anti-vWF immunobeads was added and incubated for 3 hours at room temperature. It was previously established that the binding capacity of 40 pL of anti-vWF immunobeads was in excess for 200 pL NP (data not shown). The immunobeads were then pelleted (for 10 minutes at 1,500g at room temperature) and washed three times with 10 mL PBS-Tween and resuspended in 500 pL of a 111, OOO dilution in PBS-Tween-Albumin of horseradish peroxidase-conjugated rabbit polyclonal Igs to either human IgM, IgG, or IgA (Dakopatts). After 3 hours of incubation at room temperature, the immunobeads were again pelleted and washed three times with PBS-Tween and finally resuspended in 1,000 pL of ABTS substrate solution. After 10 minutes, the color development was stopped with the addition of 100 pL concentrated acetic acid. After pelleting the immunobeads (for 10 minutes at 1,500g at room temperature), the extinction of the supernatant was measured at 414 nm. The background extinction was estimated by performing this experiment with 1 , OOO pL PBS-Tween-Albumin instead of plasma.
All experiments were performed in duplicate. Iodination of vWF. vWF was purified as described." vWF was labeled with NaIZ5I using the Iodogen method" to a specific activity Immunoprecipitation. Conditioned medium (100 pL) was mixed with 400 pL immunoprecipitation buffer (10 mmoVL Tris, 150 mmoVL NaCl, 1% Nonidet P-40, and 0.5% bovine serum albumin, pH 7.4), mixed with 5 pL serum of the patient, and rotated for 2 hours at 4°C. Twenty microliters of rabbit polyclonal Igs to human IgM (Dakopatts) was added and rotated for 1 hour at 4"C, after which 40 pL protein A-sepharose (Pharmacia, Uppsala, Sweden) was added and rotated for 1 hour at 4°C. The Sepharose beads were pelleted (for 30 seconds at 14,OOOg at room temperature) and washed four times with 1 mL of immunoprecipitation buffer. Bound protein was eluted by incubation for 5 minutes at 100°C with reducing sample buffer and analyzed by polyacrylamide gel electrophoresis (PAGE) on a 5% 25% gel in the presence of SDS, performed according to Laemmli." Competition experiments with unlabeled fragments were performed by incubating 100 pL conditioned medium, with 100 pL 1OX immunoprecipitation buffer and 800 pL of BHK 
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RESULTS

Platelet function and vWF-related activities
in plmna. The initial hemostatic data of our patient were characterized by a prolonged Ivy bleeding time (> 15 minutes; normal, c 4 minutes), absent ristocetin-induced platelet aggregation, low levels of FVII1:C (0. 10 U/mL: normal. 0.60 to 1.40 U/ mL) and vWF:Ag (0.08 U/mL; normal, 0.60 to I .40 U/mL), and very low to undetectable levels of vWF:RCoF (<O.OS U/mL: normal, 0.60 to I .40 U/mL) and vWFCBA (0.01 U/ mL: normal, 0.60 to 1.40 U/mL), confirming the diagnosis of vWD. A selective absence of the high molecular weight multimers of vWF, as seen in patients with type IIA congenital vWD. was noted (Fig 2, preinfusion value) . The absence of the high molecular weight multimers of vWF was not caused by increased proteolysis. as shown by subunit analysis of vWF. or caused by the binding of vWF to malignant lymphoma cells (results not shown).
Infirsion studies. Infusion of 3,000 U of the vWF concentrate Haemate P (Fig 2) 
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of the bleeding time. In addition, a rapid clearance to preinfusion levels of the FVlWvWF-related activities and the high molecular weight multimers of vWF was observed. Interestingly, the vWF:CBA activity remained decreased immediately after Haemate P infusion, despite normal levels of ristocetin cofactor activity and vWF antigen. Immunoprecipitation of n~W F fragments I>? /he inhibitor, To determine which part of vWF interacted with the inhibitor, recombinant fragments of vWF expressed in mammalian cells (Fig 1) were immunoprecipated. As shown in Fig 4A, the inhibitor reacted both with the GPIb binding domain and the A3 domain of vWF. but not with the A2 or the D4 domains of vWF. This indicates that either the inhibitor has an epitope present on aa 422-715 and aa 909-1 I 12 or that two anti-vWF antibodies are involved. To further show that the inhibitor reacted exclusively with the vWF GPlb and A3 domains, we performed additional inhibition experiments. Immunoprecipitation studies (Fig 4B) showed that an excess of mixed unlabeled GPlb and A3 domain could compete for the immunoprecipitation of metabolically labeled rvWF and AAl-rvWF (missing aa 478-717) by the inhibitor. These domains seem to be the only parts of vWF interacting with the inhibitor(s). To investigate the monoclonality of the in- hibitor, we performed additional immunoprecipitations of '251-vWF with serum of the patient. As shown in Fig 5 , an excess of either unlabeled recombinant GPIb fragments or unlabeled recombinant A3 fragments was able to compete for binding of the inhibitor to ' ' % W F to the same extent as unlabeled vWF, thereby excluding the presence of two anti-vWF antibodies. The culture medium, unlabeled recombinant A2 domain, and unlabeled recombinant D4 domain were unable to compete for binding of the inhibitor to Iz5I-VWF.
Inhibitor
DISCUSSION
The adhesion of platelets to the exposed subendothelium or perivascular collagen at sites of vascular injury requires the binding of v W F to these tissues.'l The high molecular weight multimers of vWF are known to play an important role in this initial phase of hemostasis by expressing numerous binding sites for collagen" and other subendothelial cons t i t u e n t~.~~ In the described patient, an IgM autoantibody was found to be involved in the pathogenesis of acquired vWD that had severe consequences in vivo.
In the last 3 years, the patient developed a progressive bleeding tendency consisting of recurrent epistaxis, easy bruising, and severe gastrointestinal blood loss, requiring almost weekly hospitalization. To achieve adequate hemostasis at times of bleeding, intensive replacement therapy with DDAVP and FVIIYvWF concentrates was instituted with only minor improvement. This finding suggested the presence of a circulating inhibitor to the EVIIuvWF complex.
Inhibitors of vWF in plasma are normally shown in mixing experiments with normal pooled plasma by their ability to inhibit an immunologic (vWF:Ag) or functional activity (vWF:RCoF) of v W F . In this patient, the mixing experiments did not indicate the presence of an inhibitor. However, the vWF:CBA activity, which reflects the in vitro ability of vWF to bind to collagen type I, was selectively inhibited. This suggests that the inhibitor was directed against an epitope involved in the binding of vWF to collagen type I or located near these collagen binding domains, causing steric hindrance of the vWF-collagen interaction.
The results of the infusion study are in agreement with this hypothesis. After Haemate P infusion, a discrepancy between the functional activities of vWF, the vWF:RCoF, and vWF:CBA activity, was noted. The vWF:RCoF and vWF:Ag activities normalized after infusion, indicating the presence of sufficient amounts of functional vWF. Nevertheless, the bleeding time remained prolonged. In contrast, the vWF:CBA activity remained decreased. This finding may indicate a correlation between the collagen-binding activity and the bleeding time in this patient.
There was a strikingly rapid clearance of the vWF-related activities vWF:Ag, vWF:RCoF, and vWFCBA and the high molecular weight multimers of v W F after infusion. As increased proteolysis of vWF and binding of v W F to lymphoma cells were ruled out, the decrease of high molecular weight multimers of v W F is probably explained by a preferential complex formation between the inhibitor and the high molecular weight multimers of vWF, as observed by others.3@' These multimers are known to possess the ristocetin cofactor activity and have numerous collagen-binding domains. Subsequently, these vWF-inhibitor complexes are rapidly cleared from the circulation by the mononuclear phagocytic system. vWF has two domains involved in the interaction with collagen type I and They reside on part of the GPIbbinding domain (aa 422-826) known as the A1 domain and the A3 domain (aa 909-11 12). With the use of several separate rvWF fragments in the immunoprecipitation experiments, we could show that the inhibitor was reactive with the GPIb and A3 domains of vWF. Despite a considerable heterogeneity between the two collagen-binding domains of vWF, the inhibitor recognized an epitope occurring on both domains. Several mouse monoclonal antibodies (MoAbs) that also inhibit the binding of vWF to collagen have been des~ribed.'~-~' Most of them were reactive either with the AlZ5 or the A3
Our autoantibody resembles the characteristics of the mouse MoAb described by Roth et alZ4 that was also reactive with both collagen-binding domains.
To our knowledge, this is the first antibody of human origin inhibiting the binding of vWF to collagen, resulting in a virtual absence of functional vWF and a concomitant bleeding tendency. In contrast to severe congenital vWD, in which there is a comparable absence of functional vWF, our patient did not suffer from muscle or joint bleedings. Apparently the amount of FV1II:C present was sufficient enough to prevent these hemophilia-like bleeding complicaing of vWF to collagen and that reacts with both the GPlb tions.
and A3 domains of vWF. Although several investigators In conclusion, in this study a case of acute vWD is deusing cultured endothelial cells have recently shown that it scribed caused by an IgM autoantibody that inhibits the bindis unlikely that subendothelial collagen is the binding site 
